MedTrace Logo

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

NCT00663052 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2012-04-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis.

Conditions

Interventions

DRUG

Etanercept

ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.

DRUG

Etanercept

ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Argentina
  • Austria
  • Belgium
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Italy
  • Mexico
  • South Korea
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663052 on ClinicalTrials.gov